FemAid, A pioneering Medical Devise company dedicated to empowering woman’s health, is pleased to announce a major achievement in the development of its groundbreaking prototyping phase and patent filing application, marking a significant step towards revolutionizing the management of urinary incontinence in women.
San Diego, CA. June 15th, 2023 FemAid, A pioneering Medical Devise company dedicated to empowering woman’s health, is pleased to announce a major achievement in the development of its groundbreaking prototyping phase and patent filing application, marking a significant step towards revolutionizing the management of urinary incontinence in women.
The FEMAID device stops leakage utilizing a Patent Applied for check valve device, which is non-surgically placed in the woman’s urethra. It is totally adjustable to fulfill a woman’s personal needs. It interrupts the flow of urine until activated by the woman applying pressure to her bladder. This overpowers the check valve and lets the urine flow. The device can be inserted or removed at any time by the woman utilizing the supplied insertion/removal stylist.
The FEMAID device is economical and easy to use. It is made with body friendly Teflon material and is designed for maximum comfort. It comes sealed with anti-bacterial numbing ointment to minimize infection and pain with personal applicator included. The woman can insert the device herself, or have a medical practitioner insert it for her. ¼””x 1”
Female Urinary Incontinence is a common and often overlooked health concern that affects over one Billion women worldwide, causing discomfort, embarrassment, and a diminished quality of life. FemAid is committed to providing women with a solution that addresses this pervasive issue, offering a non-invasive and drug-free alternative for those seeking relief.
The completion of the prototyping phase signifies a significant advancement for FemAid. Through tireless research and development efforts, the company has engineered a novel device specifically designed to target the root causes of urinary incontinence in women and breakthrough in treatment options.
FemAid is actively seeking investors who share their vision and passion for improving women's lives affected by urinary incontinence. By partnering with strategic investors, the company aims to accelerate the development process and bring this innovative device to market as soon as possible, benefiting women globally.
The next steps for FemAid involve raising development funding and navigating the FDA certification process. The company remains dedicated to adhering to the highest standards of safety and efficacy, ensuring that their device meets all regulatory requirements before becoming commercially available to women in need.
For more information about FemAid and their revolutionary non-surgical, non-drug incontinence device, please contact:
Richard Langson,CEO Awards:
FemAid Edison Award- Best Greentech
2907 Shelter Island Dr. Wall Street Journal Innovation Award
San Diego, CA 92106 Entrepreneur of the Year
775 720-6670 Popular Science Magazine: “Best of What’s New”